Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 4
2015 5
2016 2
2017 5
2018 7
2019 6
2020 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy.
Knebel FH, Barber LJ, Newey A, Kleftogiannis D, Woolston A, Griffiths B, Fenwick K, Bettoni F, Ribeiro MFSA, da Fonseca L, Costa F, Capareli FC, Hoff PM, Sabbaga J, Camargo AA, Gerlinger M. Knebel FH, et al. Cancers (Basel). 2020 Dec 11;12(12):3736. doi: 10.3390/cancers12123736. Cancers (Basel). 2020. PMID: 33322618 Free PMC article.
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T. Lau D, et al. ESMO Open. 2020 Feb;5(1):e000638. doi: 10.1136/esmoopen-2019-000638. ESMO Open. 2020. PMID: 32079623 Free PMC article. Clinical Trial.
Targeted drugs ramp up cancer mutability.
Gerlinger M. Gerlinger M. Science. 2019 Dec 20;366(6472):1452-1453. doi: 10.1126/science.aaz9900. Science. 2019. PMID: 31857471 No abstract available.
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey A, Griffiths B, Michaux J, Pak HS, Stevenson BJ, Woolston A, Semiannikova M, Spain G, Barber LJ, Matthews N, Rao S, Watkins D, Chau I, Coukos G, Racle J, Gfeller D, Starling N, Cunningham D, Bassani-Sternberg M, Gerlinger M. Newey A, et al. J Immunother Cancer. 2019 Nov 18;7(1):309. doi: 10.1186/s40425-019-0769-8. J Immunother Cancer. 2019. PMID: 31735170 Free PMC article.
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston A, Khan K, Spain G, Barber LJ, Griffiths B, Gonzalez-Exposito R, Hornsteiner L, Punta M, Patil Y, Newey A, Mansukhani S, Davies MN, Furness A, Sclafani F, Peckitt C, Jiménez M, Kouvelakis K, Ranftl R, Begum R, Rana I, Thomas J, Bryant A, Quezada S, Wotherspoon A, Khan N, Fotiadis N, Marafioti T, Powles T, Lise S, Calvo F, Guettler S, von Loga K, Rao S, Watkins D, Starling N, Chau I, Sadanandam A, Cunningham D, Gerlinger M. Woolston A, et al. Cancer Cell. 2019 Jul 8;36(1):35-50.e9. doi: 10.1016/j.ccell.2019.05.013. Cancer Cell. 2019. PMID: 31287991 Free PMC article.
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
Davidson M, Barber LJ, Woolston A, Cafferkey C, Mansukhani S, Griffiths B, Moorcraft SY, Rana I, Begum R, Assiotis I, Matthews N, Rao S, Watkins D, Chau I, Cunningham D, Starling N, Gerlinger M. Davidson M, et al. Cancers (Basel). 2019 May 27;11(5):736. doi: 10.3390/cancers11050736. Cancers (Basel). 2019. PMID: 31137920 Free PMC article.
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito R, Semiannikova M, Griffiths B, Khan K, Barber LJ, Woolston A, Spain G, von Loga K, Challoner B, Patel R, Ranes M, Swain A, Thomas J, Bryant A, Saffery C, Fotiadis N, Guettler S, Mansfield D, Melcher A, Powles T, Rao S, Watkins D, Chau I, Matthews N, Wallberg F, Starling N, Cunningham D, Gerlinger M. Gonzalez-Exposito R, et al. J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3. J Immunother Cancer. 2019. PMID: 30982469 Free PMC article.
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I. Khan K, et al. Clin Colorectal Cancer. 2019 Mar;18(1):64-71.e1. doi: 10.1016/j.clcc.2018.09.010. Epub 2018 Sep 29. Clin Colorectal Cancer. 2019. PMID: 30404764
28 results